Drug intelligence / Profile preview

pamamg4-docosahexaenoic acid-paclitaxel conjugate

Development stage: Preclinical
Lead developer: Long Island University
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

PAMAMG4-docosahexaenoic acid-paclitaxel conjugate is a dendrimer-based drug delivery system designed to improve the therapeutic index of paclitaxel in gastrointestinal cancers. It consists of a Generation 4 poly(amidoamine) (PAMAM) dendrimer conjugated to docosahexaenoic acid (DHA), an omega-3 fatty acid, and paclitaxel. The DHA component is intended to enhance cellular uptake and potentially reduce toxicity, while the dendrimer scaffold improves solubility and bioavailability. Preclinical studies in esophageal, gastric, and pancreatic cancer models have shown that this conjugate exhibits superior antiproliferative activity and induction of apoptosis (via P53 and P21 pathways) compared to free paclitaxel.

Other names: omega-3 fatty acid conjugated paclitaxel dendrimersomega3 fatty acid conjugated paclitaxel dendrimersomega 3 fatty acid conjugated paclitaxel dendrimersPAMAM-DHA-PTX

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on pamamg4-docosahexaenoic acid-paclitaxel conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pamamg4-docosahexaenoic acid-paclitaxel conjugate.

Explore the full profile